{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T14:04:56Z","timestamp":1773151496308,"version":"3.50.1"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":5814,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1999,10]]},"abstract":"<jats:sec>\n            <jats:title\/>\n            <jats:p>Peripheral vasodilation is considered an important factor in the pathophysiology of the hepatorenal syndrome (HRS). Therefore, the aim of this study was to evaluate the therapeutic potential of the vasoconstrictor ornipressin plus dopamine in the treatment of the most severe form of HRS, namely HRS type 1. Seven cirrhotic patients (creatinine clearance 15 \u00b1 1 mL\/min, UNaV 7 \u00b1 2 mmol\/24 h) with HRS type 1 were included in the study after normalization of central venous pressure with intravenous albumin and low-dose dopamine had failed to prevent further deterioration of renal function. Ornipressin was given continuously (intravenous 6 IU\/h) in combination with dopamine (2-3 \u03bcg\/kg\/min) until creatinine clearance had increased to above 40 mL\/min or adverse events prevented further treatment. HRS was reverted in 4 of 7 patients after 5 to 27 days (creatinine clearance 51 \u00b1 4 mL\/min, UNaV 47 \u00b1 11 mmol\/24 h) of treatment. Withdrawal was necessary in 1 patient after 15 days because of intestinal ischemia. Treatment failure was observed in 2 of 7 patients (creatinine clearance 19 \u00b1 10 mL\/min, UNaV 8 \u00b1 3 mmol\/24 h). Two of 4 responders had recidivant HRS 2 and 8 months after initial therapy, respectively. HRS in 1 of these patients was reverted with 18 days of ornipressin retreatment. The other patient had to be withdrawn from ornipressin after 2 hours because of ventricular tachyarrhythmia. Altogether, 3 of 7 patients survived HRS type 1, 1 after successful ornipressin therapy and liver transplantation, 1 with 2 successful courses of ornipressin, and 1 with liver transplantation after ornipressin treatment had failed. Thus, ornipressin plus dopamine can be a useful therapeutic option in patients with HRS type 1, especially as bridge to liver transplantation.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1002\/hep.510300430","type":"journal-article","created":{"date-parts":[[2004,7,28]],"date-time":"2004-07-28T07:29:13Z","timestamp":1090999753000},"page":"870-875","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":148,"title":["Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine"],"prefix":"10.1097","volume":"30","author":[{"given":"Veit","family":"G\u00fclberg","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manfred","family":"Bilzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexander L.","family":"Gerbes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"10.1002\/hep.510300430-BIB1|cit1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0016-5085(93)90031-7","article-title":"Incidence, predictive factors, and prognosis of the hepatorenal syndrome in cirrhosis with ascites","volume":"105","author":"Gin\u00e8s","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.510300430-BIB2|cit2","first-page":"75","volume-title":"The Kidney in Liver Disease","author":"Epstein","year":"1996"},{"key":"10.1002\/hep.510300430-BIB3|cit3","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1055\/s-2007-1007299","article-title":"Pathogenesis and management of the hepatorenal syndrome","volume":"14","author":"Laffi","year":"1994","journal-title":"Semin Liver Dis"},{"key":"10.1002\/hep.510300430-BIB4|cit4","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.1840080532","article-title":"Peripheral arterial vasodilation hypothesis: a proposal for the initiation of renal sodium and water retention in cirrhosis","volume":"8","author":"Schrier","year":"1988","journal-title":"Hepatology"},{"key":"10.1002\/hep.510300430-BIB5|cit5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1002\/hep.1840090312","article-title":"Atrial natriuretic factor (ANF) and renin-aldosterone in volume regulation of patients with cirrhosis","volume":"9","author":"Gerbes","year":"1989","journal-title":"Hepatology"},{"key":"10.1002\/hep.510300430-BIB6|cit6","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/00007890-199502150-00010","article-title":"Impact of pretransplant renal function on survival after liver transplantation","volume":"59","author":"Gonwa","year":"1995","journal-title":"Transplantation"},{"key":"10.1002\/hep.510300430-BIB7|cit7","first-page":"677","article-title":"Is renal dose dopamine protective or therapeutic? Yes","volume":"12","author":"Carcoana","year":"1996","journal-title":"Crit Care Med"},{"key":"10.1002\/hep.510300430-BIB8|cit8","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1001\/archinte.1975.00330070086014","article-title":"Response to dopamine in the hepatorenal syndrome","volume":"135","author":"Bennett","year":"1975","journal-title":"Arch Intern Med"},{"key":"10.1002\/hep.510300430-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1957","DOI":"10.1001\/archinte.1993.00410170025003","article-title":"Hepatorenal syndrome. New perspectives in pathogenesis and treatment","volume":"153","author":"Badalamenti","year":"1993","journal-title":"Arch Intern Med"},{"key":"10.1002\/hep.510300430-BIB10|cit10","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1136\/gut.30.1.90","article-title":"Beneficial effect of 8-ornithin vasopressin on renal dysfunction in decompensated cirrhosis","volume":"30","author":"Lenz","year":"1989","journal-title":"Gut"},{"key":"10.1002\/hep.510300430-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/0016-5085(91)90734-3","article-title":"Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor","volume":"101","author":"Lenz","year":"1991","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.510300430-BIB12|cit12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1006\/bbrc.1994.2150","article-title":"Cloning, functional expression and tissue distribution of human cDNA for the vascular-type vasopressin receptor","volume":"203","author":"Hirasawa","year":"1994","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1002\/hep.510300430-BIB13|cit13","doi-asserted-by":"crossref","first-page":"798","DOI":"10.5694\/j.1326-5377.1971.tb92555.x","article-title":"Cardivascular effects of ornithine-8-vasopressin","volume":"2","author":"Einstein","year":"1971","journal-title":"Med J Aust"},{"key":"10.1002\/hep.510300430-BIB14|cit14","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1097\/00003246-199402000-00032","article-title":"Low-dose ornipressin improves renal function in the hepatorenal syndrome","volume":"22","author":"Evrard","year":"1994","journal-title":"Crit Care Med"},{"key":"10.1002\/hep.510300430-BIB15|cit15","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0168-8278(95)80273-8","article-title":"Sustained effects of ornipressin in hepatorenal syndrome [letter]","volume":"22","author":"Giostra","year":"1995","journal-title":"J Hepatol"},{"key":"10.1002\/hep.510300430-BIB16|cit16","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/hep.510270107","article-title":"Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion","volume":"27","author":"Guevara","year":"1998","journal-title":"Hepatology"},{"key":"10.1002\/hep.510300430-BIB17|cit17","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/hep.510230122","article-title":"Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis","volume":"23","author":"Arroyo","year":"1996","journal-title":"Hepatology"},{"key":"10.1002\/hep.510300430-BIB18|cit18","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/S0168-8278(96)80297-2","article-title":"Renal and neurohumoral changes following simultaneous administration of systemic vasoconstrictors and dopamine or prostacycline in cirrhotic patients with hepatorenal syndrome","volume":"25","author":"Salo","year":"1996","journal-title":"J Hepatol"},{"key":"10.1002\/hep.510300430-BIB19|cit19","first-page":"1053","article-title":"Successful therapy of hepatorenal syndrome using the vasopressin-1-receptor agonist ornipressin","volume":"36","author":"G\u00fclberg","year":"1998","journal-title":"Z Gastroenterol"},{"key":"10.1002\/hep.510300430-BIB20|cit20","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1016\/S0016-5085(70)80066-X","article-title":"Effects of dopamine in patients with cirrhosis","volume":"58","author":"Barnardo","year":"1970","journal-title":"Gastroenterology"},{"key":"10.1002\/hep.510300430-BIB21|cit21","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1002\/hep.1840140313","article-title":"Systemic, splanchnic and renal hemodynamic effects of a dopaminergic dose of dopamine in patients with cirrhosis","volume":"14","author":"Bacq","year":"1991","journal-title":"Hepatology"},{"key":"10.1002\/hep.510300430-BIB22|cit22","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1001\/archinte.1990.00390130077010","article-title":"Renal and humoral effects of ibopamine, a dopamine agonist, in patients with liver cirrhosis","volume":"150","author":"Salerno","year":"1990","journal-title":"Arch Intern Med"},{"key":"10.1002\/hep.510300430-BIB23|cit23","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/hep.1840130116","article-title":"Selective dopamine DA1 stimulation with fenoldopam in cirrhotic patients with ascites: a systemic, splanchnic and renal hemodynamic study","volume":"13","author":"Hadengue","year":"1991","journal-title":"Hepatology"},{"key":"10.1002\/hep.510300430-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1002\/hep.510290629","article-title":"Reversal of type 1 hepatorenal syndrome with the administration of midodrine and octreotide","volume":"29","author":"Angeli","year":"1999","journal-title":"Hepatology"},{"key":"10.1002\/hep.510300430-BIB25|cit25","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/0950-3528(92)90040-L","article-title":"Pathophysiology and treatment of ascites and hepatorenal syndrome","volume":"6","author":"Gentilini","year":"1992","journal-title":"Ballieres Clin Gastroenterol"},{"key":"10.1002\/hep.510300430-BIB26|cit26","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1001\/jama.1981.03310350020015","article-title":"Infection of pulmonary artery catheters in critically ill patients","volume":"245","author":"Michel","year":"1981","journal-title":"JAMA"},{"key":"10.1002\/hep.510300430-BIB27|cit27","doi-asserted-by":"crossref","first-page":"923","DOI":"10.7326\/0003-4819-72-6-923","article-title":"Functional renal failure in cirrhosis. Recovery after portacaval shunt","volume":"72","author":"Schroeder","year":"1970","journal-title":"Ann Intern Med"},{"key":"10.1002\/hep.510300430-BIB28|cit28","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/ki.1979.8","article-title":"Effects of a portacaval or peritoneovenous shunt on renin in the hepatorenal syndrome","volume":"15","author":"Schroeder","year":"1979","journal-title":"Kidney Int"},{"issue":"Suppl","key":"10.1002\/hep.510300430-BIB29|cit29","first-page":"114A","article-title":"TIPS for hepatorenal syndrome [Abstr]","volume":"20","author":"Ochs","year":"1994","journal-title":"Hepatology"},{"key":"10.1002\/hep.510300430-BIB30|cit30","first-page":"1169","article-title":"Improvement of hepatorenal syndrome by transjugular intrahepatic portosystemic shunt","volume":"90","author":"Spahr","year":"1995","journal-title":"Am J Gastroenterol"},{"key":"10.1002\/hep.510300430-BIB31|cit31","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1016\/S0140-6736(97)24010-9","article-title":"Transjugular intrahepatic portosystemic stent-shunt for hepatorenal syndrome","volume":"349","author":"Brensing","year":"1997","journal-title":"Lancet"},{"key":"10.1002\/hep.510300430-BIB32|cit32","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1002\/hep.510280219","article-title":"Transjugular intrahepatic portosystemic shunt in hepatorenal syndrome: effects on renal function and vasoactive systems","volume":"28","author":"Guevara","year":"1998","journal-title":"Hepatology"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.510300430","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-199910000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,1]],"date-time":"2024-12-01T11:25:36Z","timestamp":1733052336000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-199910000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1999,10]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1999]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.510300430","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[1999,10]]}}}